phenoperidine

Phenoperidine is an opioid pain killer—a narcotic analgesic.{{medcn|date=December 2014}}

It is a derivative of isonipecotic acid, like pethidine, and is metabolized in part to norpethidine. Its potency range is due to method of ingestion. figure 20–80 times as potent as pethidine as an analgesic. The greatly increased potency essentially eliminates the toxic effects of norpethidine accumulation which are seen when pethidine is administered in high doses or for long periods of time.{{cite book | vauthors = Lamberth C, Dinges J | page = 29 |title=Bioactive carboxylic compound classes : pharmaceuticals and agrochemicals |publisher=Wiley-VCH Verlag |location=Weinheim, Germany |isbn=978-3-527-33947-1|date=2016-08-22 }}

Phenoperidine was first synthesized in 1957 by Paul Janssen, of the company now known as Janssen Pharmaceutica, who was seeking better opioid pain-killers.{{cite journal | vauthors = López-Muñoz F, Alamo C | title = The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice | journal = Brain Research Bulletin | volume = 79 | issue = 2 | pages = 130–141 | date = April 2009 | pmid = 19186209 | doi = 10.1016/j.brainresbull.2009.01.005 | s2cid = 7720401 }} His two prototype drugs were methadone and pethidine, each which had been invented in 1930s by Otto Eisleb, who worked for IG Farben. His initial work starting with methadone yielded dextromoramide in 1954. Janssen then turned to making pethidine analogues, due in part to the less complicated chemistry of the compound. During his explorations, he replaced the methyl group attached to the pethidine nitrogen with a phenylhydroxypropyl group, and this yielded phenoperidine, in 1957. Phenoperidine was determined to have decreased stability and enhanced lipophilicity compared to pethidine. Soon after, studies in mice showed that phenoperidine was over 100 times more potent than pethidine.

In 1958, the same line of work yielded "one of the greatest advances of the 20th century psychiatry", haloperidol, as well as diphenoxylate, which lacked the opioid's analgesic properties but still stopped peristalsis in the intestines, a typical side effect of opioids; Janssen brought diphenoxylate to market as a drug to treat diarrhea.{{cite book | vauthors = Sneade W | title = Drug Discovery: A History. | publisher = John Wiley & Sons | date = 2005 | isbn = 978-0-471-89979-2 }}{{rp|124}} And through further advances, Janssen created fentanyl in 1960, which proved to be ten times more potent than phenoperidine.{{cite journal | vauthors = Stanley TH | title = The fentanyl story | journal = The Journal of Pain | volume = 15 | issue = 12 | pages = 1215–1226 | date = December 2014 | pmid = 25441689 | doi = 10.1016/j.jpain.2014.08.010 | doi-access = free }}

In 1959, the combination of phenoperidine and haloperidol was first used in Europe in anesthesia to induce a detached, pain free state called neuroleptic analgesia; the use of that mixture boomed in early 1960s but was overtaken by the combination of fentanyl and droperidol, which was widely used through the 1980s. These combination approaches were not adopted in the US.{{cite book | vauthors =Eger EI, Saidman L, Westhorpe R | title = The Wondrous Story of Anesthesia. | publisher = Springer Science & Business Media | date = 2013 | isbn = 978-1-4614-8441-7 }}{{rp|644}}

In 1961 phenoperidine was added to the 1931 Convention for Limiting the Manufacture and Regulating the Distribution of Narcotic Drugs by the World Health Organization via the Single Convention on Narcotic Drugs.{{cite web | series = WHO Technical Report Series | issue = 211 | date = 1961 | url = http://whqlibdoc.who.int/trs/WHO_TRS_211.pdf | author = Expert Committee on Addiction-Producing Drugs | title = Eleventh Report }}WHO Executive Board. 17 April 1961 [http://apps.who.int/iris/bitstream/10665/136008/1/EB28_2_eng.pdf Action in Respect of the International Convention on Narcotic Drugs.]

In the US it is classified as a Drug Enforcement Administration (DEA) Schedule I controlled substance opiate with a corresponding code 9641.{{cite web|title=Memo: Overview of the September 14, 2010, DSaRM Advisory Committee Meeting to Discuss the Drug Enforcement Administration (DEA) Request for an Abuse Potential Evaluation and Scheduling Recommendation for Dextromethorphan (DXM) |url=https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/drugsafetyandriskmanagementadvisorycommittee/ucm224446.pdf|archive-url=https://web.archive.org/web/20100910121128/http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM224446.pdf|url-status=dead|archive-date=September 10, 2010|website=U.S. Food and Drug Administration|access-date=22 November 2014}}

{{Reflist|2}}

{{refbegin}}

• {{cite journal | vauthors = Kintz P, Godelar B, Mangin P, Lugnier AA, Chaumont AJ | title = Simultaneous determination of pethidine (meperidine), phenoperidine, and norpethidine (normeperidine), their common metabolite, by gas chromatography with selective nitrogen detection | journal = Forensic Science International | volume = 43 | issue = 3 | pages = 267–273 | date = December 1989 | pmid = 2613140 | doi = 10.1016/0379-0738(89)90154-0 }}
• {{cite journal | vauthors = Claris O, Bertrix L | title = [Phenoperidine: pharmacology and use in pediatric resuscitation] | language = French | journal = Pédiatrie | volume = 43 | issue = 6 | pages = 509–513 | year = 1988 | pmid = 3186421 }}
• {{ cite encyclopedia | title = Antipsychotics - Reference pathway | encyclopedia = Kyoto Encyclopedia of Genes and Genomes | publisher = Kanehisa Laboratories, Kyoto University, University of Tokyo | url = http://www.genome.ad.jp/dbget-bin/show_pathway?map07028+D02611 | access-date = 2007-01-16 }}

{{refend}}

{{General anesthetics}}

{{Analgesics}}

{{Opioidergics}}

Category:General anesthetics

Category:4-Phenylpiperidines

Category:Secondary alcohols

Category:Carboxylate esters

Category:Mu-opioid receptor agonists

Category:Ethyl esters